Trial Profile
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2019
Price :
$35
*
At a glance
- Drugs PF 06835919 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Jun 2018 Status changed from recruiting to completed.
- 27 Mar 2018 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
- 27 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 30 Mar 2018.